Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Repligen Cp (RGEN)

201.99   -13.29 (-6.17%) 01-27 03:28
Open: 214.74 Pre. Close: 215.28
High: 215.205 Low: 200.6279
Volume: 679,635 Market Cap: 11,052M
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 215.303 - 216.75 216.75 - 217.95
Low: 197.982 - 199.328 199.328 - 200.443
Close: 200.017 - 202.203 202.203 - 204.016

Technical analysis

as of: 2021-01-26 4:48:18 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 245.44     One year: 265.10
Support: Support1: 182.90    Support2: 152.17
Resistance: Resistance1: 210.14    Resistance2: 226.97
Pivot: 209.63
Moving Average: MA(5): 214.03     MA(20): 204.59
MA(100): 179.07     MA(250): 142.63
MACD: MACD(12,26): 6.34     Signal(9): 6.64
Stochastic oscillator: %K(14,3): 61.63     %D(3): 71.35
RSI: RSI(14): 48.47
52-week: High: 226.97  Low: 78.41  Change(%): 98.6
Average Vol(K): 3-Month: 43987  10-Days: 42880

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
RGEN has closed above bottom band by 25.7%. Bollinger Bands are 22.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 10 Dec 2020
Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters' Option - GlobeNewswire

Mon, 07 Dec 2020
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock - GlobeNewswire

Mon, 07 Dec 2020
Repligen Corporation Prices Public Offering of Shares of Common Stock - GlobeNewswire

Thu, 05 Nov 2020
Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance - GlobeNewswire

Tue, 27 Oct 2020
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions - GlobeNewswire

Thu, 22 Oct 2020
Repligen to Report Third Quarter 2020 Financial Results - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Instruments & Supplies
Shares Out. (M) 55
Shares Float (M) 49
% Held by Insiders 7.07
% Held by Institutions 83.54
Shares Short (K) 1,380
Shares Short P. Month (K) 1,640

Stock Financials

EPS 0.820
EPS Est This Year 0.590
EPS Est Next Year 0.740
Book Value (p.s.) 21.380
Profit Margin 13.40
Operating Margin 18.20
Return on Assets (ttm) 2.6
Return on Equity (ttm) 4.0
Qtrly Rev. Growth 35.4
Gross Profit (p.s.) 2.789
Sales Per Share 5.978
EBITDA (p.s.) 1.557
Qtrly Earnings Growth 777.20
Operating Cash Flow (M) 65
Levered Free Cash Flow (M) 25

Stock Valuations

PE Ratio 246.33
PEG Ratio
Price to Book value 9.45
Price to Sales 33.79
Price to Cash Flow 168.93

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.